COMPOSITION : Each tablet contains:-
M.O.A. : Gliclazide belongs to a blood sugar lowering group of medicines called sulfonylurea. Gliclazide increases the amount of insulin released by the pancreas, and thereby decreases the blood sugar level.
- Pharmacotherapeutic group: sulphonamides, urea derivative
- ATC code: A10BB09
- Gliclazide is a hypoglycaemic sulphonylurea oral antidiabetic active substance differing from other related compounds by an N-containing heterocyclic ring with an endocyclic bond.
- Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans. Increase in postprandial insulin and C-peptide secretion persists after two years of treatment.
- In addition to these metabolic properties, gliclazide has haemovascular properties.
- Effects on insulin release
- In type 2 diabetics, gliclazide restores the first peak of insulin secretion in response to glucose and increases thesecond phase of insulin secretion. A significant increase in insulin response is seen in response to stimulation
induced by a meal or glucose.
- Haemovascular properties:
- Gliclazide decreases microthrombosis by two mechanisms which may be involved in complications of diabetes:
- A partial inhibition of platelet aggregation and adhesion, with a decrease in the markers of platelet activation (beta thromboglobulin, thromboxane B2).
- An action on the vascular endothelium fibrinolytic activity with an increase in tPA activity.
Plasma levels increase progressively during the first 6 hours, reaching a plateau which is maintained from the
sixth to the twelfth hour after administration. Intra-individual variability is low.
Gliclazide is completely absorbed. Food intake does not affect the rate or degree of absorption.
Plasma protein binding is approximately 95%. The volume of distribution is around 30 litres. A single daily intake of Diamicron 30 mg MR Tablets maintains effective gliclazide plasma concentrations over 24 hours.
Gliclazide is mainly metabolised in the liver and excreted in the urine: less than 1% of the unchanged form is found in the urine. No active metabolites have been detected in plasma.
The elimination half-life of gliclazide varies between 12 and 20 hours.
INDICATION : Type 2 diabetes mellitus.
DOSAGE : As directed by the physician
SIDE EFFECTS : Visual disturbances, Indigestion, Widespread blistering and peeling of skin, Decrease in the number of cells in the blood, Abdominal pain, Vomiting, Rashes, Urge to vomit, Skin rashes, Angio edema, Excessive fall in blood glucose level, Diarrhea, Abnormalities of blood cells, Constipation